Top

BMC Cancer

Published in:

01-12-2021 | osteosarcoma | Research

The tumor immune microenvironment and immune-related signature predict the chemotherapy response in patients with osteosarcoma

Authors: Lijiang He, Hainan Yang, Jingshan Huang

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Genome-wide expression profiles have been shown to predict the response to chemotherapy. The purpose of this study was to develop a novel predictive signature for chemotherapy in patients with osteosarcoma.

Methods

We analysed the relevance of immune cell infiltration and gene expression profiles of the tumor samples of good responders with those of poor responders from the TARGET and GEO databases. Immune cell infiltration was evaluated using a single-sample gene set enrichment analysis (ssGSEA) and the CIBERSORT algorithm between good and poor chemotherapy responders. Differentially expressed genes were identified based on the chemotherapy response. LASSO regression and binary logistic regression analyses were applied to select the differentially expressed immune-related genes (IRGs) and developed a predictive signature in the training cohort. A receiver operating characteristic (ROC) curve analysis was employed to assess and validate the predictive accuracy of the predictive signature in the validation cohort.

Results

The analysis of immune infiltration showed a positive relationship between high-level immune infiltration and good responders, and T follicular helper cells and CD8 T cells were significantly more abundant in good responders with osteosarcoma. Two hundred eighteen differentially expressed genes were detected between good and poor responders, and a five IRGs panel comprising TNFRSF9, CD70, EGFR, PDGFD and S100A6 was determined to show predictive power for the chemotherapy response. A chemotherapy-associated predictive signature was developed based on these five IRGs. The accuracy of the predictive signature was 0.832 for the training cohort and 0.720 for the validation cohort according to ROC analysis.

Conclusions

The novel predictive signature constructed with five IRGs can be effectively utilized to predict chemotherapy responsiveness and help improve the efficacy of chemotherapy in patients with osteosarcoma.

Available only for authorised users

Jafari F, Javdansirat S, Sanaie S, Naseri A, Shamekh A, Rostamzadeh D, et al. Osteosarcoma: a comprehensive review of management and treatment strategies. Ann Diagn Pathol. 2020;49:151654. https://doi.org/10.1016/j.anndiagpath.2020.151654.CrossRefPubMed

Czarnecka AM, Synoradzki K, Firlej W, Bartnik E, Sobczuk P, Fiedorowicz M, et al. Molecular Biology of Osteosarcoma. Cancers. 2020;12(8):1-27.

Eaton BR, Schwarz R, Vatner R, Yeh B, Claude L, Indelicato DJ, et al. Osteosarcoma. Pediatr Blood Cancer. 2020:e28352:S1-7.

Zhu W, Zhu L, Bao Y, Zhong X, Chen Y, Wu Q. Clinical evaluation of neoadjuvant chemotherapy for osteosarcoma. J BUON. 2019;24(3):1181–5.PubMed

Bacci G, Ferrari S, Mercuri M, Bertoni F, Picci P, Manfrini M, et al. Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand. 1998;69(3):230–6. https://doi.org/10.3109/17453679809000921.CrossRefPubMed

Joo MW, Kang YK, Yoo CY, Cha SH, Chung YG. Prognostic significance of chemotherapy-induced necrosis in osteosarcoma patients receiving pasteurized autografts. PLoS One. 2017;12(2):e0172155. https://doi.org/10.1371/journal.pone.0172155.CrossRefPubMedPubMedCentral

Marec-Berard P, Dalban C, Gaspar N, Brugieres L, Gentet J, Lervat C, et al. A multicentric randomized phase II clinical trial evaluating high-dose thiotepa as adjuvant treatment to standard chemotherapy in patients with resectable relapsed osteosarcoma. Eur J Cancer (Oxford, England : 1990). 2020;125:58–68.CrossRef

Ferrari S, Bielack S, Smeland S, Longhi A, Egerer G, Sundby Hall K, et al. EURO-B.O.S.S.: a European study on chemotherapy in bone-sarcoma patients aged over 40: outcome in primary high-grade osteosarcoma. Tumori. 2018;104(1):30–6. https://doi.org/10.5301/tj.5000696.CrossRefPubMed

10.

Senerchia A, Macedo C, Ferman S, Scopinaro M, Cacciavillano W, Boldrini E, et al. Results of a randomized, prospective clinical trial evaluating metronomic chemotherapy in nonmetastatic patients with high-grade, operable osteosarcomas of the extremities: a report from the Latin American group of osteosarcoma treatment. Cancer. 2017;123(6):1003–10. https://doi.org/10.1002/cncr.30411.CrossRefPubMed

11.

Song K, Song J, Lin K, Chen F, Ma X, Jiang J, et al. Survival analysis of patients with metastatic osteosarcoma: a surveillance, epidemiology, and end results population-based study. Int Orthop. 2019;43(8):1983–91. https://doi.org/10.1007/s00264-019-04348-4.CrossRefPubMed

12.

Xu J, Xie L, Guo W. Neoadjuvant chemotherapy followed by delayed surgery: is it necessary for all patients with nonmetastatic high-grade pelvic osteosarcoma? Clin Orthop Relat Res. 2018;476(11):2177–86. https://doi.org/10.1097/CORR.0000000000000387.CrossRefPubMedPubMedCentral

13.

Tsuda Y, Tsoi K, Parry M, Stevenson J, Fujiwara T, Sumathi V, et al. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma. Bone Joint J. 2020;6:795–803.CrossRef

14.

An O, Song Y, Ke X, So J, Sundar R, Yang H, et al. “3G” Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy. Cancer Res. 2021;81(10):2788–98.

15.

Tanioka M, Fan C, Parker J, Hoadley K, Hu Z, Li Y, et al. Integrated analysis of RNA and DNA from the phase III trial CALGB 40601 identifies predictors of response to Trastuzumab-based Neoadjuvant chemotherapy in HER2-positive breast Cancer. Clin Cancer Res. 2018;24(21):5292–304. https://doi.org/10.1158/1078-0432.CCR-17-3431.CrossRefPubMedPubMedCentral

16.

Powles R, Wali V, Li X, Barlow W, Nahleh Z, Thompson A, et al. Analysis of pre- and Posttreatment tissues from the SWOG S0800 trial reveals an effect of Neoadjuvant chemotherapy on the breast Cancer genome. Clin Cancer Res. 2020;26(8):1977–84. https://doi.org/10.1158/1078-0432.CCR-19-2405.CrossRefPubMedPubMedCentral

17.

Mo X, Huang X, Feng Y, Wei C, Liu H, Ru H, et al. Immune infiltration and immune gene signature predict the response to fluoropyrimidine-based chemotherapy in colorectal cancer patients. Oncoimmunology. 2020;9(1):1832347. https://doi.org/10.1080/2162402X.2020.1832347.CrossRefPubMedPubMedCentral

18.

Edwardson D, Parissenti A, Kovala A. Chemotherapy and inflammatory cytokine Signalling in Cancer cells and the tumour microenvironment. Adv Exp Med Biol. 2019;1152:173–215. https://doi.org/10.1007/978-3-030-20301-6_9.CrossRefPubMed

19.

Foukakis T, Lovrot J, Matikas A, Zerdes I, Lorent J, Tobin N, et al. Immune gene expression and response to chemotherapy in advanced breast cancer. Br J Cancer. 2018;118(4):480–8. https://doi.org/10.1038/bjc.2017.446.CrossRefPubMedPubMedCentral

20.

Sui S, An X, Xu C, Li Z, Hua Y, Huang G, et al. An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer. Theranostics. 2020;10(26):11938–49. https://doi.org/10.7150/thno.49451.CrossRefPubMedPubMedCentral

21.

Jiang Y, Xie J, Huang W, Chen H, Xi S, Han Z, et al. Tumor immune microenvironment and Chemosensitivity signature for predicting response to chemotherapy in gastric Cancer. Cancer Immunol Res. 2019;7(12):2065–73. https://doi.org/10.1158/2326-6066.CIR-19-0311.CrossRefPubMed

22.

Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–59.CrossRefPubMedPubMedCentral

23.

Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7. https://doi.org/10.1038/nmeth.3337.CrossRefPubMedPubMedCentral

24.

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–95. https://doi.org/10.1016/j.immuni.2013.10.003.CrossRefPubMed

25.

Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14(1):7. https://doi.org/10.1186/1471-2105-14-7.CrossRef

26.

Kobayashi E, Masuda M, Nakayama R, Ichikawa H, Satow R, Shitashige M, et al. Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma. Mol Cancer Ther. 2010;9(3):535–44. https://doi.org/10.1158/1535-7163.MCT-09-0774.CrossRefPubMed

27.

Vella S, Tavanti E, Hattinger C, Fanelli M, Versteeg R, Koster J, et al. Targeting CDKs with Roscovitine increases sensitivity to DNA damaging drugs of human osteosarcoma cells. PLoS One. 2016;11(11):e0166233. https://doi.org/10.1371/journal.pone.0166233.CrossRefPubMedPubMedCentral

28.

Kelly A, Haibe-Kains B, Janeway K, Hill K, Howe E, Goldsmith J, et al. MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32. Genome Med. 2013;5(1):2. https://doi.org/10.1186/gm406.CrossRefPubMedPubMedCentral

29.

Wang D, Wu Y, Huang J, Wang W, Xu M, Jia J, et al. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance. Chinese J Cancer. 2016;35(1):47. https://doi.org/10.1186/s40880-016-0109-z.CrossRef

30.

Chen R, Li D, Zheng M, Chen B, Wei T, Wang Y, et al. FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1. J Cell Mol Med. 2020;24(3):2123–34. https://doi.org/10.1111/jcmm.14763.CrossRefPubMedPubMedCentral

31.

Xiao Z, Qu Z, Chen Z, Fang Z, Zhou K, Huang Z, et al. LncRNA HOTAIR is a prognostic biomarker for the proliferation and Chemoresistance of colorectal Cancer via MiR-203a-3p-mediated Wnt/ß-catenin signaling pathway. Cell Physiol Biochemistry. 2018;46(3):1275–85. https://doi.org/10.1159/000489110.CrossRef

32.

Bhattacharya S, Andorf S, Gomes L, Dunn P, Schaefer H, Pontius J, et al. ImmPort: disseminating data to the public for the future of immunology. Immunol Res. 2014;58(2–3):234–9. https://doi.org/10.1007/s12026-014-8516-1.CrossRefPubMed

33.

Smrke A, Anderson PM, Gulia A, Gennatas S, Huang PH, Jones RL. Future Directions in the Treatment of Osteosarcoma. Cells. 2021;10(1):172.CrossRefPubMedPubMedCentral

34.

Marchandet L, Lallier M, Charrier C, Baud’huin M, Ory B, Lamoureux F. Mechanisms of Resistance to Conventional Therapies for Osteosarcoma. Cancers. 2021;13(4):683.CrossRefPubMedPubMedCentral

35.

Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 2020;53:100715. https://doi.org/10.1016/j.drup.2020.100715.CrossRefPubMed

36.

Hong W, Yuan H, Gu Y, Liu M, Ji Y, Huang Z, et al. Immune-related prognosis biomarkers associated with osteosarcoma microenvironment. Cancer Cell Int. 2020;20(1):83. https://doi.org/10.1186/s12935-020-1165-7.CrossRefPubMedPubMedCentral

37.

Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983–91. https://doi.org/10.1200/JCO.2014.58.1967.CrossRefPubMed

38.

Sota Y, Naoi Y, Tsunashima R, Kagara N, Shimazu K, Maruyama N, et al. Construction of novel immune-related signature for prediction of pathological complete response to neoadjuvant chemotherapy in human breast cancer. Ann Oncol. 2014;25(1):100–6. https://doi.org/10.1093/annonc/mdt427.CrossRefPubMed

39.

Shi W, Dong L, Sun Q, Ding H, Meng J, Dai G. Follicular helper T cells promote the effector functions of CD8(+) T cells via the provision of IL-21, which is downregulated due to PD-1/PD-L1-mediated suppression in colorectal cancer. Exp Cell Res. 2018;372(1):35–42. https://doi.org/10.1016/j.yexcr.2018.09.006.CrossRefPubMed

40.

Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29(1):235–71. https://doi.org/10.1146/annurev-immunol-031210-101324.CrossRefPubMed

41.

Wang YJ, Fletcher R, Yu J, Zhang L. Immunogenic effects of chemotherapy-induced tumor cell death. Genes & diseases. 2018;5(3):194–203. https://doi.org/10.1016/j.gendis.2018.05.003.CrossRef

42.

Wong DY, Ong WW, Ang WH. Induction of immunogenic cell death by chemotherapeutic platinum complexes. Angewandte Chemie (International ed in English). 2015;54(22):6483–7. https://doi.org/10.1002/anie.201500934.CrossRef

43.

Jaime-Sanchez P, Uranga-Murillo I, Aguilo N, Khouili SC, Arias MA, Sancho D, et al. Cell death induced by cytotoxic CD8(+) T cells is immunogenic and primes caspase-3-dependent spread immunity against endogenous tumor antigens. J Immunother Cancer. 2020;8(1):e000528.CrossRefPubMedPubMedCentral

44.

Wu J, Waxman DJ. Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy. Cancer Lett. 2018;419:210–21. https://doi.org/10.1016/j.canlet.2018.01.050.CrossRefPubMedPubMedCentral

45.

Wang J, Hu C, Wang J, Shen Y, Bao Q, He F, et al. Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma. J Immunother. 2019;42(9):321–30.CrossRefPubMed

46.

Kallarackal J, Burger F, Bianco S, Romualdi A, Schad M. A 3-gene biomarker signature to predict response to taxane-based neoadjuvant chemotherapy in breast cancer. PLoS One. 2020;15(3):e0230313. https://doi.org/10.1371/journal.pone.0230313.CrossRefPubMedPubMedCentral

47.

Xie Y, Lu W, Wang S, Tang X, Tang H, Zhou Y, et al. Validation of the 12-gene predictive signature for adjuvant chemotherapy response in lung Cancer. Clin Cancer Res. 2019;25(1):150–7. https://doi.org/10.1158/1078-0432.CCR-17-2543.CrossRefPubMed

48.

Zhao Y, Yang X. The hippo pathway in chemotherapeutic drug resistance. Int J Cancer. 2015;137(12):2767–73. https://doi.org/10.1002/ijc.29293.CrossRefPubMed

49.

Zhou L, Tang J, Hu F, Liao Y, Li R, Zhou Y, et al. Effects of different levels of TGF-β expression and tumor cell necrosis rates in osteosarcoma on the chemotherapy resistance of osteosarcoma. J Bone Oncol. 2020;23:100299. https://doi.org/10.1016/j.jbo.2020.100299.CrossRefPubMedPubMedCentral

50.

Wu TT, Chen YF, Hastie T, Sobel E, Lange K. Genome-wide association analysis by lasso penalized logistic regression. Bioinformatics. 2009;25(6):714–21.CrossRefPubMedPubMedCentral

51.

Chester C, Sanmamed MF, Wang J, Melero I. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood. 2018;131(1):49–57. https://doi.org/10.1182/blood-2017-06-741041.CrossRefPubMed

52.

Wang Z, Kong D, Li Y, Sarkar FH. PDGF-D signaling: a novel target in cancer therapy. Curr Drug Targets. 2009;10(1):38–41. https://doi.org/10.2174/138945009787122914.CrossRefPubMed

53.

Zhang M, Liu T, Xia B, Yang C, Hou S, Xie W, et al. Platelet-derived growth factor D is a prognostic biomarker and is associated with platinum resistance in epithelial ovarian Cancer. Int J Gynecol Cancer. 2018;28(2):323–31. https://doi.org/10.1097/IGC.0000000000001171.CrossRefPubMed

54.

Olsen RS, Dimberg J, Geffers R, Wågsäter D. Possible role and therapeutic target of PDGF-D Signalling in colorectal Cancer. Cancer Investig. 2019;37(2):99–112. https://doi.org/10.1080/07357907.2019.1576191.CrossRef

55.

Jacobs J, Deschoolmeester V, Zwaenepoel K, Rolfo C, Silence K, Rottey S, et al. CD70: An emerging target in cancer immunotherapy. Pharmacol Ther. 2015;155:1–10. https://doi.org/10.1016/j.pharmthera.2015.07.007.CrossRefPubMed

56.

Luo T, Liu Q, Tan A, Duan L, Jia Y, Nong L, et al. Mesenchymal stem cell-secreted exosome promotes Chemoresistance in breast Cancer via enhancing miR-21-5p-mediated S100A6 expression. Mol Ther Oncolytics. 2020;19:283–93. https://doi.org/10.1016/j.omto.2020.10.008.CrossRefPubMedPubMedCentral

57.

Man TK, Chintagumpala M, Visvanathan J, Shen J, Perlaky L, Hicks J, et al. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res. 2005;65(18):8142–50. https://doi.org/10.1158/0008-5472.CAN-05-0985.CrossRefPubMed

58.

Ochi K, Daigo Y, Katagiri T, Nagayama S, Tsunoda T, Myoui A, et al. Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol. 2004;24(3):647–55.PubMed

Title: The tumor immune microenvironment and immune-related signature predict the chemotherapy response in patients with osteosarcoma
Authors: Lijiang He
Hainan Yang
Jingshan Huang
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: osteosarcoma
Osteosarcoma
Cytostatic Therapy
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08328-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Characteristics of interval gastric neoplasms detected within two years after negative screening endoscopy among Koreans

Risk and prognostic factors of breast cancer with liver metastases

Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019

A novel ferroptosis-related 12-gene signature predicts clinical prognosis and reveals immune relevancy in clear cell renal cell carcinoma

Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma

CT based automatic clinical target volume delineation using a dense-fully connected convolution network for cervical Cancer radiation therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer